-
Deep Learning Model Predicts Future Breast Cancer Risk
drugs
December 19, 2019
A deep learning (DL) model can predict which women are at risk for subsequent development of breast cancer, with higher accuracy than density-based models ...
-
Anastrozole Tied to Lasting Reduction in Breast Cancer Risk
drugs
December 18, 2019
Anastrozole is associated with a long-term reduction in breast cancer risk, even after treatment, according to a study published online ...
-
Shedding Pounds May Shrink Breast Cancer Risk
drugs
December 18, 2019
Losing weight might be a powerful weapon against breast cancer, a new study suggests.
-
Many Long-Term Breast Cancer Survivors Die From Other Causes
drugs
December 17, 2019
Non-breast cancer (non-BC) causes of death represent a considerable proportion of deaths among patients diagnosed with BC, according to a study published online in Cancer.
-
SABCS: Roche's Perjeta builds case as HER2-positive add-on
fiercepharma
December 12, 2019
Roche is in the hot seat as its longtime breast cancer blockbuster Herceptin faces a growing stable of biosimilar challengers. But other drugs in Roche's portfolio are on the rise.
-
Two Drugs Make Inroads Against Aggressive Breast Cancers
drugs
December 12, 2019
Two experimental drugs show real promise against an aggressive, treatment-resistant form of breast cancer that's spread to other parts of the body, researchers say.
-
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority
En-CPhI.CN
December 03, 2019
A new breast cancer drug shown to significantly reduce the risk of cancer recurrence has received approval in Singapore – at least six months ahead of its expected schedule.
-
“Upstar” against Breast Cancer—CDK 4/6 Inhibitors: Which has the Biggest Potential among the Three?
PharmaSources/Dopine
August 20, 2019
Targeted therapies have played an increasingly important role in tumor treatment in recent years.
-
Explanation found for high mortality in breast cancer patients taking aspirin
pharmaceutical-technology
August 13, 2019
Researchers from the University of North Carolina (UNC) at Chapel Hill, US, have identified that wide variations in the mortality risk of breast cancer patients taking aspirin could be related to the DNA methylation profile in their tumours or peripheral
-
Verzenio Demonstrates Significant Improvement in Overall Survival in Breast Cancer Trial
americanpharmaceuticalreview
August 01, 2019
Eli Lilly and Company announced Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial.